
Primovist®
Primovist® is a liver-specific contrast agent for magnetic resonance imaging.
Liver. Specific. Confidence.
Primovist® significantly improves the detection and characterization of focal liver lesions and is particularly valuable in the detection of small lesions.1 Radiologists experience an increase in diagnostic confidence in the diagnosis of liver disease. After Primovist®-MRI no additional imaging procedure is required.2

What is Primovist®?
Primovist® is a 0.25 molar hepatocyte specific MRI contrast agent. It has combined properties of an extracellular agent and a liver specific agent.
How does Primovist® work?
The active ingredient of Primovist® is gadoxetate disodium. It is a gadolinium containing contrast agent in which the Gd3+ ion is firmly bound in a complex. Primovist® is first distributed in the extracellular space of the body, allowing traditional T1-weighted dynamic vascular images to be acquired. The vascular phase is followed by a gradual transition of the agent into hepatocytes through transporters within the cell membranes (transitional phase). The intracellular enhancement reaches a plateau about 10-20 minutes after Primovist® injection.
This accumulation of Primovist® in the liver cells allows an additional delayed imaging phase to take place with an extended imaging window. During this phase, healthy liver parenchyma is positively enhanced in T1-weighted images.
Application
Primovist® is provided in ready-to-use 10 mL prefilled glass syringes and in vials.
How is Primovist® administered?
Primovist® is administered intravenously as a fast bolus (1-2 mL/sec). Use of an injector is recommended and there is some evidence to suggest that a slower injection speed of 1 mL/sec may be beneficial, due to a reduction in imaging artifacts.
Indications
Primovist® is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-weighted MRI.6

1 Halavaara J et al. Comput Assist Tomogr. 2006;30:345–54.
2 Endrikat J et al. J Magn Reson Imaging. 2015;42(3):634–43.
3 Endrikat J et al. Acta Radiol. 2016; 57(11):1326–33.
4 Hammerstingl R, et al. Eur Radiol. 2008;18(3):457 – 467
5 Zech CJ, et al. Br J Surg. 2014;101(6):613–21.
6 Primovist® SmPC July 2016
.
Primovist® is:
- provided as a ready-to-use solution of 0.25 mmol Gd/mL.
- for diagnostic use by intravenous administration only.
- a stable colorless solution of low osmolality and low viscosity.
Physicochemical data
Parameter | Gd-EOB-DTPA |
Viscosity (at 37°C) | 1.19 mPa.s |
Osmolality (at 37°C) | 688 mOsm/kg H2O |
Density (at 37°C) | 1.0881 g/mL |
Relaxivity r1 (at 1.5 Tesla, in plasma, 37°C) | 6.9 l/(mmol-1s-1) [Rohrer et al.] |
Relaxivity r2 (at 1.5 Tesla, in plasma, 37°C) | 8.7 l/(mmol-1s-1) [Rohrer et al.] |
Primovist® administration at 25 µmol/kg BW provided improved diagnostic confidence in 90% of patients in phase 2 studies.
Primovist® is supplied in ready-to-use, prefilled 10 mL syringes containing 10 mL (1814 mg Gd-EOB-DTPA) of solution.
Studies
Validation of DCE-MRI for Liver Malignancies
Perfusion parameters of dynamic Primovist®-enhanced MRI correlate with the proliferation and...
News on Benign Liver Lesions
Differentiation between the benign liver lesion focal nodular hyperplasia (FNH) and hepatocellular...
Primovist® in Korean Guidelines
A Korean study confirms the advantages of having included specific features of HCC...
Primovist® in the Elderly
Gadoxetate disodium shows a good safety profile in patients older than 65 years...
Interviews

"Radiologists should stand up for themselves"
Takamichi Murakami is Professor and Chairman of the Department of Radiology at Kinki University Faculty of Medicine in Osaka, Japan.
The Japanese way of managing HCC
Professor Masayuki Kanematsu, Gifu University Hospital, is one of the leading Japanese liver imaging specialists.

Disclaimer
Effective November 23, 2017, the European Commission (EC) issued a final decision in the Article 31 referral procedure evaluating the presence of gadolinium (Gd) in the body and gadolinium-based contrast agents (GBCAs) to the EU Member States and countries in the European Economic Area (EEA). In general, the EC has adopted the opinion of the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The EC decision is two-fold:
- Suspension of all multipurpose linear GBCAs, including Bayer’s Magnevist® i.v.
- Updates to the labels / prescribing information of all GBCAs remaining on the market, including Bayer’s Gadovist® 1.0 and its specialty linear GBCAs Primovist® and Magnevist® 2 mmol / L intra-articular formulation.
Importantly, EMA’s CHMP in their final opinion confirms that “there is currently no evidence that gadolinium deposition in the brain has caused any harm to patients; however EMA has recommended restrictions for some intravenous linear agents in order to prevent any risk that could potentially be associated with gadolinium brain deposition.”
Magnevist® is not available in all countries.